Academy of Medical Sciences, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450052, China.
Cell Biol Toxicol. 2023 Oct;39(5):2011-2032. doi: 10.1007/s10565-021-09686-x. Epub 2022 Jan 13.
Increasing evidence suggests that targeting ubiquitin-specific peptidase 8 (USP8) serves as an attractive anti-cancer strategy. However, the role of USP8 inhibitor, DUB-IN-1, in esophageal squamous cell carcinoma (ESCC) cells still needs to be explored. Here, immunohistochemistry was employed to examine the expression of USP8 in ESCC tissues. Cell Counting Kit-8 (CCK-8) was used to evaluate cell proliferation ability, and propidium iodide (PI) was selected to test the effect of DUB-IN-1 on cell cycle. AnnexinV-FITC/PI staining and the activity of caspase 3 were detedcted to evaluate apoptosis. Transmission electron microscope, microtubule-associated protein 1 light-chain 3 (LC3) expression, and acridine orange (AO) staining were selected to check if there was autophagy. Comet assay and γ-H2AX immunofluorescence was used to monitor DNA damage. Rescue experiment was used to determine the key role of of p53 in cell cycle, apoptosis, and autophagy. Results revealed that the leve of USP8 was higher in ESCC tissues than that in tissues adjacent to carcinoma. DUB-IN-1, an USP8 inhibitor, caused DNA damage, led to G2/M phase block by p53-p21 axis, and triggered apoptosis by regulating the p53 target proteins including Bax, Noxa, and Puma. Besides, DUB-IN-1 could stimulate autophagy through p53-dependent adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) activation. Taken together, this study revealed the cytotoxic effects and the mechanism of DUB-IN-1, which indicated that DUB-IN-1 may be a novel inhibitor targeting USP8 that can kill ESCC cells. USP8 inhibitor, DUB-IN-1, treatment could inhibit esophageal squamous cell carcinoma cell growth and induce G2/M cell cycle arrest, apoptosis, and autophagy by DNA damage-induced p53 activation. DUB-IN-1 treatment led to G2/M cell cycle arrest by upregulating the protein level of p21 and triggered apoptosis by modulating the p53 target proteins including Bax, Noxa, and Puma. Meanwhile, DUB-IN-1 treatment stimulated protective autophagy through p53-dependent AMPK activation. Collectively, these findings suggested that DNA damage-triggered p53 activation, p53-Puma/Noxa/Bax, p53-p21, and p53-AMPK pathways were all involved in the effect of DUB-IN-1.
越来越多的证据表明,靶向泛素特异性肽酶 8(USP8)是一种有吸引力的抗癌策略。然而,USP8 抑制剂 DUB-IN-1 在食管鳞状细胞癌(ESCC)细胞中的作用仍有待探索。本研究采用免疫组织化学方法检测 ESCC 组织中 USP8 的表达。细胞计数试剂盒-8(CCK-8)用于评估细胞增殖能力,碘化丙啶(PI)用于检测 DUB-IN-1 对细胞周期的影响。用 AnnexinV-FITC/PI 染色和 caspase 3 活性检测评估细胞凋亡。用透射电子显微镜、微管相关蛋白 1 轻链 3(LC3)表达和吖啶橙(AO)染色检测自噬。彗星试验和 γ-H2AX 免疫荧光检测监测 DNA 损伤。通过挽救实验确定 p53 在细胞周期、细胞凋亡和自噬中的关键作用。结果显示,USP8 在 ESCC 组织中的表达水平高于癌旁组织。USP8 抑制剂 DUB-IN-1 可引起 DNA 损伤,通过 p53-p21 轴导致 G2/M 期阻滞,并通过调节 Bax、Noxa 和 Puma 等 p53 靶蛋白引发细胞凋亡。此外,DUB-IN-1 还可通过 p53 依赖性腺苷 5'-单磷酸(AMP)激活蛋白激酶(AMPK)激活诱导自噬。综上所述,本研究揭示了 DUB-IN-1 的细胞毒性作用和作用机制,表明 DUB-IN-1 可能是一种新型靶向 USP8 的抑制剂,可杀伤 ESCC 细胞。USP8 抑制剂 DUB-IN-1 通过激活 DNA 损伤诱导的 p53 抑制食管鳞状细胞癌细胞生长并诱导 G2/M 细胞周期阻滞、细胞凋亡和自噬。DUB-IN-1 通过上调 p21 蛋白水平导致 G2/M 细胞周期阻滞,并通过调节 Bax、Noxa 和 Puma 等 p53 靶蛋白触发细胞凋亡。同时,DUB-IN-1 通过 p53 依赖性 AMPK 激活诱导保护性自噬。总之,这些发现表明,DNA 损伤诱导的 p53 激活、p53-Puma/Noxa/Bax、p53-p21 和 p53-AMPK 途径均参与了 DUB-IN-1 的作用。